Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

Article summary

Cardiff Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead drug candidate, onvansertib, for the treatment of chronic myelomonocytic leukemia (CMML).